Search Result

Results for "

protein dimerization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aldehyde Dehydrogenase (ALDH) (1) Amyloid-β (1) Apoptosis (4) Autophagy (1) Bacterial (2) Biochemical Assay Reagents (5) c-Myc (1) Caspase (1) CDK (1) Drug Derivative (1) Drug Intermediate (3) Drug Isomer (1) EGFR (16) Estrogen Receptor/ERR (1) FGFR (1) FKBP (2) Glycosidase (1) HIV (1) HSP (1) HuR (1) mRNA (2) OLIG2 (1) Orthopoxvirus (1) p38 MAPK (1) PARP (1) PDGFR (3) PKA (1) PKG (1) Potassium Channel (1) PROTACs (1) Raf (1) RIP kinase (1) STAT (1) ULK (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (2) Infection (6) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Transcription Factors (1) mRNA (2)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13992

AP20187 Maximum Cited Publications 48 Publications Verification B/B Homodimerizer	FKBP	Metabolic Disease
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.

HY-P4121

L17E	Potassium Channel	Inflammation/Immunology Cancer
L17E is an attenuated cationic amphiphilic lytic (ACAL) peptide that can be used to deliver a variety of macromolecules, including proteins, antibodies, and DNA nanostructures. L17E inserts and cleaves the membrane structure through electrostatic interaction, enabling intracellular escape. The efficiency of L17E-mediated delivery is strongly correlated with the expression level of KCNN4 (the gene encoding the calcium-activated potassium channel KCa3.1). L17E also promotes the cellular uptake of macromolecules by inducing micropinocytosis. L17E can be further optimized and improved through dimerization strategies and in combination with other delivery systems, such as nuclear localization signal peptides and cell membrane-coated nanoparticles .

HY-179078

CT-179	OLIG2 Apoptosis Caspase PARP	Neurological Disease Cancer
CT-179 is a brain-penetrant and orally active OLIG2 inhibitor with a human IC₅₀ of 1250 nM. CT-179 disrupts OLIG2 dimerization, phosphorylation, and DNA binding, blocking OLIG2-driven transcription. CT-179 induces G₂/M phase arrest and increases G₀ population. CT-179 induces apoptosis by reducing anti-apoptotic proteins and increasing cleaved caspase-3 and cleaved PARP. CT-179 can be used for the research of subgroup medulloblastoma .

HY-131015

HaXS8	Biochemical Assay Reagents	Others
HaXS8 is a dimerizer that can promote a covalent and irreversible intracellular dimerization of HaloTag and SNAP-tagged proteins of interest. HaXS8 does not interfere with PI3K/mTOR signaling .

HY-145560

Claficapavir A1752	HIV	Infection
Claficapavir (A1752) is a specific nucleocapsid protein (NC) inhibitor with an IC₅₀ around 1 μM. Claficapavir strongly binds the HIV-1 NC (K_d=20 nM) thereby inhibiting the chaperone properties of NC and leading to good antiviral activity against the HIV-1 .

HY-150259

MDEG-541	PROTACs c-Myc	Cancer
MDEG-541 is a potent MYC-MAX degrader. MDEG-541 is a PROTAC that based on the MYC-MAX dimerization inhibitor 10058-F4 derivative 28RH and Thalidomide (HY-14658). MDEG-541 shows antiproliferative activity. MDEG-541 decreases the expression of GSPT1, MYC, GSPT2, PLK1 protein .

HY-126316

Zapalog 1 Publications Verification	FKBP	Others
Zapalog is a photocleavable small-molecule heterodimerizer that can be used to repeatedly initiate, and instantaneously terminate, a physical interaction between two target proteins. Zapalog dimerizes any two proteins tagged with the FKBP and DHFR domains until exposure to light causes its photolysis .

HY-160783

SRI-43265	HuR	Cancer
SRI-43265 (compound 40) is an inhibitor of human antigen R protein (HuR) dimerization, and HuR multimers have been implicated in cancer and inflammatory pathogenesis .

HY-P10438

TAT-Braftide	Raf	Cancer
TAT-Braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by TAT-Braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of RAF kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-13636A

Fulvestrant (S enantiomer) ICI 182780 (S enantiomer); ZD 9238 (S enantiomer); ZM 182780 (S enantiomer)	Drug Isomer Estrogen Receptor/ERR p38 MAPK Apoptosis	Cancer
Fulvestrant (ICI 182780; ZD 9238) S enantiomer is the S-enantiomer of Fulvestrant (HY-13636), a potent estrogen receptor inhibitor. Fulvestrant binds to and blocks the estrogen receptor, promotes its degradation, and thereby inhibits receptor dimerization, nucleocytoplasmic shuttling and transcriptional activity. Fulvestrant effectively blocks estrogen signaling, MAPK pathway activation and ER-regulated protein expression. Fulvestrant induces apoptosis, inhibits the proliferation of breast cancer and prolactinoma cells, and reduces the mineralization level, alkaline phosphatase activity and osteocalcin expression of preosteoblasts. Prenatal exposure to Fulvestrant impairs ovarian follicular development and causes ovarian structural damage. Fulvestrant has been widely used in studies related to breast cancer, prolactinoma and other conditions .

HY-153890

NVOC cage-TMP-Halo	Biochemical Assay Reagents	Others
NVOC cage-TMP-Halo is a cell-permeable and photoactivatable protein dimerization inducer. NVOC cage-TMP-Halo can rapidly and reversibly control protein localization in living cells. NVOC cage-TMP-Halo can be used for dynamic cellular processes research .

HY-P11498

Cyclomarin monomer-2	Drug Intermediate Bacterial	Infection
Cyclomarin monomer-2 (Compound 10), a cyclomarin monomer, is a pre-dimerization precursor that can form Homo-BacPROTACs targeting the degradation of ClpC1. Cyclomarin monomer-2 binds to the Mtb ClpC1 protein with a K_D of 4.0 nM. The MIC of Cyclomarin monomer-2 against the Mtb H37Rv standard strain is 3.1 μM. Cyclomarin monomer-2 can be used as a key intermediate in the development of Homo-BacPROTACs .

HY-124843

LLL3 1 Publications Verification CLT-005	STAT Apoptosis	Cancer
LLL3 (CLT-005) is a STAT3 inhibitor. LLL3 inhibits dimerization and phosphorylation of STAT3, thereby preventing intraconuclear transfer of STAT3 and inhibits the expression of STAT3 dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of STAT3 persistent activation types of cancer .

HY-P11497

Cyclomarin monomer-1	Drug Intermediate Bacterial	Infection
Cyclomarin monomer-1 (Compound 5), a cyclomarin monomer, is a pre-dimerization precursor that can form Homo-BacPROTACs targeting the degradation of ClpC1. Cyclomarin monomer-1 binds to the Mtb ClpC1 protein with a K_D of 3.5 nM. The MIC of Cyclomarin monomer-1 against the Mtb H37Rv standard strain is 1.6 μM. Cyclomarin monomer-1 can be used as a key intermediate in the development of Homo-BacPROTACs .

HY-121817

Sulfiram	Aldehyde Dehydrogenase (ALDH) Drug Intermediate Amyloid-β	Infection Neurological Disease
Sulfiram is a very weak aldehyde dehydrogenase (ALDH) inhibitor, with an IC₅₀ value of 413 μM against Saccharomyces cerevisiae ALDH. As a photochemical precursor, Sulfiram undergoes photoconversion to form Disulfiram (HY-B0240), a potent ALDH inhibitor. Sulfiram inhibits the dimerization of the extracellular domain fragment (amino acid residues 230-624) of amyloid precursor protein (APP), alters the monomer-dimer equilibrium, induces conformational changes in the fragment, and enhances the production of sAPPα via α-cleavage of APP. Sulfiram can be used in research related to scabies and Alzheimer's disease .

HY-E70696

EGFR C797S/L858R Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR C797S/L858R Recombinant Human Active Protein Kinase is a recombinant EGFR C797S/L858R protein that can be used to study EGFR C797S/L858R-related functions .

HY-E70763

PDGFRalpha T674I Recombinant Human Active Protein Kinase	PDGFR	Cancer
PDGFRalpha is a receptor tyrosine kinases that stimulate cell survival, proliferation and motility. Upon PDGF binding, the receptor dimerizes and undergoes a conformational change, which activates the kinase domain. PDGFRalpha T674I is a mutant of PDGFRalpha. PDGFRalpha T674I Recombinant Human Active Protein Kinase is a recombinant PDGFRalpha T674I protein that can be used to study PDGFRalpha T674I-related functions .

HY-P10319

RI-STAD-2	PKA	Cardiovascular Disease Cancer
RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .

HY-E70704

EGFR G719C Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR G719C Recombinant Human Active Protein Kinase is a recombinant EGFR G719C protein that can be used to study EGFR G719C-related functions .

HY-E70695

EGFR C797S Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR C797S Recombinant Human Active Protein Kinase is a recombinant EGFR C797S protein that can be used to study EGFR C797S-related functions .

HY-E70707

EGFR L858R Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L858R Recombinant Human Active Protein Kinase is a recombinant EGFR L858R protein that can be used to study EGFR L858R-related functions .

HY-E70708

EGFR L861Q Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L861Q Recombinant Human Active Protein Kinase is a recombinant EGFR L861Q protein that can be used to study EGFR L861Q-related functions .

HY-E70706

EGFR L718Q Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR L718Q Recombinant Human Active Protein Kinase is a recombinant EGFR L718Q protein that can be used to study EGFR L718Q-related functions .

HY-E70705

EGFR G719S Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR G719S Recombinant Human Active Protein Kinase is a recombinant EGFR G719S protein that can be used to study EGFR G719S-related functions .

HY-E70709

EGFR T790M Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR T790M Recombinant Human Active Protein Kinase is a recombinant EEGFR T790M protein that can be used to study EGFR T790M-related functions .

HY-E70697

EGFR d746-750 Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750 Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750 protein that can be used to study EGFR d746-750-related functions .

HY-E70703

EGFR d752-759 Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d752-759 Recombinant Human Active Protein Kinase is a recombinant EGFR d752-759 protein that can be used to study EGFR d752-759-related functions .

HY-E70711

EGFR T790M/L858R Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR T790M/L858R Recombinant Human Active Protein Kinase is a recombinant EGFR T790M/L858R protein that can be used to study EGFR T790M/L858R-related functions .

HY-E70701

EGFR d747-749/A750P Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d747-749/A750P Recombinant Human Active Protein Kinase is a recombinant EGFR d747-749/A750P protein that can be used to study EGFR d747-749/A750P-related functions .

HY-E70698

EGFR d746-750/C797S Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/C797S Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/C797S protein that can be used to study EGFR d746-750/C797S-related functions .

HY-E70702

EGFR d747-752/P753S Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d747-752/P753S Recombinant Human Active Protein Kinase is a recombinant EGFR d747-752/P753S protein that can be used to study EGFR d747-752/P753S-related functions .

HY-E70762

PDGFRalpha D842V Recombinant Human Active Protein Kinase	PDGFR	Cancer
PDGFRalpha is a receptor tyrosine kinases that stimulate cell survival, proliferation and motility. Upon PDGF binding, the receptor dimerizes and undergoes a conformational change, which activates the kinase domain. PDGFRalpha D842V is a mutant of PDGFRalpha. PDGFRalpha D842V Recombinant Human Active Protein Kinase is a recombinant PDGFRalpha D842V protein that can be used to study PDGFRalpha D842V-related functions .

HY-E70764

PDGFRalpha V561D Recombinant Human Active Protein Kinase	PDGFR	Cancer
PDGFRalpha is a receptor tyrosine kinases that stimulate cell survival, proliferation and motility. Upon PDGF binding, the receptor dimerizes and undergoes a conformational change, which activates the kinase domain. PDGFRalpha V561D is a mutant of PDGFRalpha. PDGFRalpha V561D Recombinant Human Active Protein Kinase is a recombinant PDGFRalpha V561D protein that can be used to study PDGFRalpha V561D-related functions .

HY-137378A

8-Br-PET-cGMP	PKG	Cardiovascular Disease Inflammation/Immunology
8-Br-PET-cGMP is an agonist of cGMP-dependent protein kinase type I (cGKI). 8-Br-PET-cGMP promotes the dimerization of cGKI and activates its catalytic activity by binding to the regulatory domain of cGKI. 8-Br-PET-cGMP can be used to study the role of cGMP signaling pathways in cell growth, vasodilation, and smooth muscle cell function .

HY-174568

Human NFKB2 mRNA	mRNA	Inflammation/Immunology
Human NFKB2 mRNA encodes the human nuclear factor kappa B subunit 2 (NFKB2) protein, a subunit of the transcription factor complex nuclear factor-kappa-B (NFkB). The NFkB complex is expressed in numerous cell types and functions as a central activator of genes involved in inflammation and immune function. NFKB2 can function as either a transcriptional activator or repressor depending on its dimerization partner.

HY-E70717

FGFR1 V561M Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR1 has been implicated in numerous cancer types including non-small cell lung cancer (NSCLC). FGFR1 is activated upon FGF binding to its extracellular domain, resulting in protein dimerization and transautophosphorylation of the intracellular tyrosine kinase domains. FGFR1 V561M gatekeeper mutation drives Fexagratinib (AZD4547) (HY-13330) resistance through STAT3 Activation and EMT. FGFR1 V561M Recombinant Human Active Protein Kinase is a recombinant FGFR1 V561M protein that can be used to study FGFR1 V561M-related functions .

HY-D2935

CoDi2	Biochemical Assay Reagents	Others
CoDi3 is a covalent dimerization inducer. CoDi3 can specifically, covalently and irreversibly induce the dimerization of two proteins that have been fused with O6-alkylguanine-DNA alkyltransferase (AGT, also known as SNAP-tag) in living cells. CoDi3 can act as a "sensor" for protein-protein interactions .

HY-D2995

CoDi3	Biochemical Assay Reagents	Others
CoDi3 is a covalent dimerization inducer. CoDi3 can specifically, covalently and irreversibly induce the dimerization of two proteins that have been fused with O6-alkylguanine-DNA alkyltransferase (AGT, also known as SNAP-tag) in living cells. CoDi3 can act as a "sensor" for protein-protein interactions .

HY-D2981

CoDi1	Biochemical Assay Reagents	Others
CoDi1 is an effective chemical crosslinking agent. CoDi1 can achieve covalent and irreversible dimerization of AGT/SNAP tag fusion proteins in living cells .

HY-174721

Human EGFR mRNA	mRNA	Cancer
Human EGFR mRNA encodes the human epidermal growth factor receptor (EGFR) protein, a member of the protein kinase superfamily. IGF1R plays a critical role in transformation events. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation.

HY-181062

VWK147	HSP Apoptosis Autophagy ULK RIP kinase CDK	Cancer
VWK147 is a second-generation HSP90 C-terminal domain (CTD) inhibitor. VWK147 targets the CTD dimerization interface, prevents HSP90 CTD dimerization, disrupts co-chaperone PPID binding to HSP90 CTD, and inhibits HSP90 chaperone function dependent on dimerization. VWK147 reduces protein levels of HSP90 client proteins ULK1, RIPK1, and CDK4 without inducing a heat shock response. VWK147 induces cell death, including apoptosis, in Cisplatin (HY-17394)-sensitive and -resistant urothelial carcinoma cells. VWK147 induces LC3-II accumulation, inhibits autophagosome-lysosome fusion to block canonical autophagy, and induces non-canonical LC3 lipidation independent of ULK1 and PIK3C3 complexes. VWK147 can be used for the research of urothelial carcinoma .

HY-E70699

EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/T790M/C797S protein that can be used to study EGFR d746-750/T790M/C797S-related functions .

HY-E70700

EGFR d746-750/T790M/C797S/L858R Recombinant Human Active Protein Kinase	EGFR	Cancer
EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR d746-750/T790M/C797S/L858R Recombinant Human Active Protein Kinase is a recombinant EGFR d746-750/T790M/C797S/L858R protein that can be used to study EGFR d746-750/T790M/C797S/L858R-related functions .

HY-131570

JZ-4109	Glycosidase	Neurological Disease
JZ-4109 is a β-Glucocerebrosidase (GCase) modulator with an IC₅₀ of 8 nM for wild-type recombinant GCase. JZ-4109 binds to an allosteric site at the GCase dimer interface, stabilizes wild-type and GCase ^N370S mutant GCase, induces GCase dimerization. JZ-4109 increases GCase protein abundance. JZ-4109 can be used for the research of Parkinson's diseas .

HY-180785

G243-1720	Orthopoxvirus	Infection
G243-1720 is a potent, orally active, broad-spectrum anti-orthopoxvirus agent that functions by targeting the OPG57 (F13) protein and inducing its dimerization. G243-1720 effectively inhibits the replication of various poxviruses, but has no inhibitory effect on non-poxviruses. G243-1720 prevents the formation of extracellular membrane virus particles and the spread between cells. G243-1720 significantly reduces the viral load of monkeypox virus (MPXV) in the lungs of mice

HY-P3051A

CKS-17 (dimer)	Drug Derivative	Infection Inflammation/Immunology
CKS-17 (dimer) is the dimer of CKS-17 (HY-P3051). CKS-17 (dimer) can be prepared by introducing a naturally occurring cysteine at the carboxyl terminus and dimerizing via a cysteine-disulfide bond. CKS-17 is a synthetic retroviral envelope peptide. CKS-17 has a highly conserved amino acid sequence present in the transmembrane envelope proteins of numerous animal and human retroviruses. As an immunomodulatory epitope, CKS-17 exhibits inhibitory properties on a variety of immune functions .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library

704 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 704 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Type